Literature DB >> 22383231

Behavioural symptoms and impairments in multiple sclerosis: a systematic review and meta-analysis.

Eija Rosti-Otajärvi1, Päivi Hämäläinen.   

Abstract

Behavioural problems are not well recognized in multiple sclerosis (MS). In this review we aimed to evaluate the prevalence of behavioural symptoms and impairments in MS. A systematic search was carried out from MEDLINE, PsycINFO, Web of Science, CINAHL and COCHRANE. In total, 23 studies (1831 participants) were identified. Based on the literature search, behavioural symptoms and impairments are observed in MS. Aggression (23%), apathy (22%), euphoria (12%) and lack of insight (11%) were the most frequent symptoms, and adjustment disorder (17%) the most frequent impairment. Severe mental disorders are more infrequent than changes in behaviour, manner of reaction, and way of action. In conclusion the objective behavioural impairments and especially subjective symptoms are present in patients with MS. These manifestations should be taken into account in the diagnostics and treatment of the disease.

Entities:  

Mesh:

Year:  2012        PMID: 22383231     DOI: 10.1177/1352458512439437

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

Review 1.  Social Cognition in Multiple Sclerosis: a Meta-Analysis.

Authors:  Emre Bora; Serkan Özakbaş; Dennis Velakoulis; Mark Walterfang
Journal:  Neuropsychol Rev       Date:  2016-06-20       Impact factor: 7.444

2.  Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.

Authors:  Vicente Lieberknecht; Stella C Junqueira; Mauricio P Cunha; Thaís A Barbosa; Luiz F de Souza; Igor S Coelho; Adair R S Santos; Ana Lúcia S Rodrigues; Alcir L Dafré; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

3.  Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis.

Authors:  Masaaki Niino; Nobuhiro Mifune; Tatsuo Kohriyama; Masahiro Mori; Takashi Ohashi; Izumi Kawachi; Yuko Shimizu; Hikoaki Fukaura; Ichiro Nakashima; Susumu Kusunoki; Katsuichi Miyamoto; Kazuto Yoshida; Takashi Kanda; Kyoichi Nomura; Takashi Yamamura; Fumihito Yoshii; Jun-ichi Kira; Shunya Nakane; Kazumasa Yokoyama; Makoto Matsui; Yusei Miyazaki; Seiji Kikuchi
Journal:  BMC Neurol       Date:  2014-01-06       Impact factor: 2.474

4.  Behavioral Changes in Patients with Multiple Sclerosis.

Authors:  Mirjam R Heldner; Sigal Kaufmann-Ezra; Klemens Gutbrod; Corrado Bernasconi; Sandra Bigi; Verena Blatter; Heinrich P Mattle; René M Müri; Rajeev K Verma; Christian P Kamm
Journal:  Front Neurol       Date:  2017-08-28       Impact factor: 4.003

5.  Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

Authors:  Fernando Cavalcanti; Elena Gonzalez-Rey; Mario Delgado; Clara P Falo; Leyre Mestre; Carmen Guaza; Francisco O'Valle; Michele M P Lufino; Jordi Xaus; Cristina Mascaró; Serena Lunardi; Natalia Sacilotto; Paola Dessanti; David Rotllant; Xavier Navarro; Mireia Herrando-Grabulosa; Carlos Buesa; Tamara Maes
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525

6.  A cell-based drug delivery platform for treating central nervous system inflammation.

Authors:  Oren Levy; Veit Rothhammer; Ivan Mascanfroni; Zhixiang Tong; Rui Kuai; Michael De Biasio; Qingping Wang; Tahir Majid; Christelle Perrault; Ada Yeste; Jessica E Kenison; Helia Safaee; Juliet Musabeyezu; Martina Heinelt; Yuka Milton; Heidi Kuang; Haoyue Lan; William Siders; Marie-Christine Multon; Jonathan Rothblatt; Salam Massadeh; Manal Alaamery; Ali H Alhasan; Francisco J Quintana; Jeffrey M Karp
Journal:  J Mol Med (Berl)       Date:  2021-01-04       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.